Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB announced the publication of clinical trial results showing the potential of nadunolimab combined with pembrolizumab in treating solid tumors. The study involved 15 heavily pre-treated patients who had previously progressed on immune checkpoint inhibitors, demonstrating a median overall survival of 19.7 months and a 60% disease control rate. The combination therapy was particularly effective in patients with high levels of immune cell infiltration in the tumor microenvironment, suggesting a new treatment avenue for patients resistant to current immunotherapies.
More about Cantargia AB
Cantargia AB is a biotechnology company that develops antibody-based treatments for life-threatening diseases. It has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. The company’s oncology program focuses on the antibody nadunolimab (CAN04), primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia is listed on Nasdaq Stockholm.
Average Trading Volume: 933,364
Current Market Cap: SEK407.2M
For an in-depth examination of CANTA stock, go to TipRanks’ Stock Analysis page.